Gilead Sciences has said it will charge governments $2,340 for a 5-day course of remdesivir, a drug that has been shown to shorten the time it takes Covid-19 patients to recover.
The US biotech group said government healthcare programmes in developed countries would be charged a flat fee of $390 per vial for the drug. A five-day treatment uses six vials.
Remdesivir, a medicine once seen as a potential Ebola treatment, is the only branded drug to receive emergency use approval from US regulators for treating Covid-19.
您已閱讀15%（520字），剩余85%（3061字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。